Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Blood

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/BLOOD.V99.1.10PMID 11756146
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Hydroxyurea : Effects on Hemoglobin F Production in Patients With Sickle Cell Anemia

  2003cited by this paper
• Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group.

  1999cited by this paper
• Hydroxyurea in Children with Sickle Cell Disease: Impact on Splenic Function and Compliance with Therapy

  1998cited by this paper
• Decrease of very late activation antigen-4 and CD36 on reticulocytes in sickle cell patients treated with hydroxyurea.

  1997cited by this paper
• Three-year follow-up of hydroxyurea treatment in severely ill children with sickle cell disease. The French Study Group on Sickle Cell Disease.

  1997cited by this paper
• Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Multicenter Study of Hydroxyurea.

  1997cited by this paper
• Three-Year Follow-Up of Hydroxyurea Treatment in Severely Ill Children with Sickle Cell Disease

  1997cited by this paper
• St. Jude Children's Research Hospital.

  1997cited by this paper
• Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial.

  1996cited by this paper
• Hydroxyurea therapy in children severely affected with sickle cell disease.

  1996cited by this paper
• Clinical and hematologic effects of hydroxyurea in children with sickle cell anemia.

  1996cited by this paper
• A multiparameter analysis of sickle erythrocytes in patients undergoing hydroxyurea therapy.

  1996cited by this paper
• Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.

  1995cited by this paper
• Mortality in sickle cell disease. Life expectancy and risk factors for early death.

  1994cited by this paper
• Induction of fetal hemoglobin production in subjects with sickle cell anemia by oral sodium phenylbutyrate.

  1994cited by this paper
• Hydroxyurea affects cell morphology, cation transport, and red blood cell adhesion in cultured vascular endothelial cells.

  1994cited by this paper
• A short-term trial of butyrate to stimulate fetal-globin-gene expression in the beta-globin disorders.

  1993cited by this paper
• Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia.

  1992cited by this paper
• Pain in sickle cell disease. Rates and risk factors.

  1991cited by this paper
• Treatment of sickle cell anemia with hydroxyurea and erythropoietin.

  1990cited by this paper
• Fetal hemoglobin, sickling, and sickle cell disease.

  1990cited by this paper
• Mortality in children and adolescents with sickle cell disease. Cooperative Study of Sickle Cell Disease.

  1989cited by this paper
• Hydroxyurea-induced augmentation of fetal hemoglobin production in patients with sickle cell anemia.

  1987cited by this paper
• The relationship between fetal hemoglobin and disease severity in children with sickle cell anemia.

  1987cited by this paper
• Children's Hospital of Philadelphia.

  1975cited by this paper
• [Fetal hemoglobin].

  1959cited by this paper

• Assessing multilevel barriers to hydroxyurea adherence in youth with sickle cell disease using pharmacy‐based refill records

  2024cites this paper
• Towards genomic medicine: a tailored next-generation sequencing panel for hydroxyurea pharmacogenomics in Tanzania

  2024cites this paper
• Practical guide for disease-modifying medication management of children and adolescents with sickle cell disease.

  2024cites this paper
• Randomized pilot trial of cell phone support to improve medication adherence among adolescents and young adults with chronic health conditions

  2024cites this paper
• The Present Condition of Sickle Cell Disease: An Overview of Stem Cell Transplantation as a Cure

  2023cites this paper
• Is Hydroxyurea Treatment Changing the Life of Children with Sickle Cell Disease?

  2023cites this paper
• Males with sickle cell disease have higher risks of cerebrovascular disease, increased inflammation, and a reduced response to hydroxyurea

  2023cites this paper
• Hydroxyurea treatment for sickle cell anemia during pregnancy and lactation: Current evidence and knowledge gaps

  2023cites this paper
• Sickle Cell Disease in Children and Adolescents: A Review of the Historical, Clinical, and Public Health Perspective of Sub-Saharan Africa and Beyond

  2022cites this paper
• Common Genetic Variants of Fetal Hemoglobin Modify Hematological Phenotypes in MDS/MPN/Myeloma Patients Receiving Cytotoxic Drugs

  2022cites this paper
• Hydroxyurea decouples persistent F-cell elevation and induction of γ-globin.

  2022cites this paper
• Adherence to hydroxyurea, health-related quality of life domains and attitudes towards a smartphone app among Irish adolescents and young adults with sickle cell disease

  2021cites this paper
• Sickle Cell Anemia: Variants in the CYP2D6, CAT, and SLC14A1 Genes Are Associated With Improved Hydroxyurea Response

  2020cites this paper
• Association of HMIP1 C-893A polymorphism and disease severity in patients with sickle cell anemia

  2020cites this paper
• Use of Wise Device Technology to Measure Adherence to Hydroxyurea Therapy in Youth With Sickle Cell Disease

  2020cites this paper
• A Systematic Review of Medication Adherence Interventions in Pediatric Sickle Cell Disease.

  2020cites this paper
• Sickle cell disease

  2020cites this paper
• Clinical implementation of pharmacogenetics and model‐informed precision dosing to improve patient care

  2020cites this paper
• HABIT efficacy and sustainability trial, a multi-center randomized controlled trial to improve hydroxyurea adherence in youth with sickle cell disease: a study protocol

  2019cites this paper
• A Glimpse into Pharmacogenomics in Africa

  2019cites this paper
• Vascularized Microfluidics and the Blood–Endothelium Interface

  2019cites this paper
• Electronic Hydroxyurea Adherence : A Multidimensional Electronic Adherence Intervention That Improves Hydroxyurea Adherence in Children With Sickle Cell Disease

  2019cites this paper
• Targeting sickle cell disease root-cause pathophysiology with small molecules

  2019cites this paper
• A Multidimensional Electronic Hydroxyurea Adherence Intervention for Children With Sickle Cell Disease: Single-Arm Before-After Study

  2019influential citation
• CLINICAL AND HEMATOLOGICAL EFFECTS OF HYDROXYUREA THERAPY IN MANAGEMENT OF SICKLE CELL ANEMIA

  2019influential citation
• Association of Xmn1 polymorphism and consanguineous marriage with fetal hemoglobin in Syrian patients with sickle cell disease

  2019cites this paper
• The effects of hydroxycarbamide on the plasma proteome of children with sickle cell anaemia

  2019cites this paper
• Sickle Cell Anemia Patients in Use of Hydroxyurea: Association between Polymorphisms in Genes Encoding Metabolizing Drug Enzymes and Laboratory Parameters

  2018cites this paper
• Retinal microcirculation imaging in sickle cell disease patients.

  2018cites this paper
• Serum of sickle cell disease patients contains fetal hemoglobin silencing factors secreted from leukocytes

  2018influential citation
• Fetal Hemoglobin Induction by Epigenetic Drugs.

  2018cites this paper
• Hematopoietic stem cell transplantation for sickle cell disease: Progress and challenges

  2018cites this paper
• Red blood cell transfusion therapy for sickle cell patients with frequent painful events

  2018cites this paper
• Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: A randomized phase 1 study

  2017cites this paper
• An age dependent response to hydroxyurea in pediatric sickle cell anemia patients with alpha thalassemia trait.

  2017cites this paper
• The genetics of red blood cell density, a biomarker of clinical severity in sickle cell disease

  2017cites this paper
• A Retrospective Review to Determine If Children with Sickle Cell Disease Receive Hydroxyurea Monitoring

  2017cites this paper
• Disease burden and the role of pharmacogenomics in African populations

  2017cites this paper
• Enhancing Effect of Hydroxyurea on Hb F in Sickle Cell Disease: Ten-Year Egyptian Experience

  2017cites this paper
• Genetic Basis and Genetic Modifiers of β-Thalassemia and Sickle Cell Disease.

  2017cites this paper
• Key Pharmacogenomic Considerations for Sickle Cell Disease Patients

  2017cites this paper
• Barriers to hydroxyurea adherence and health‐related quality of life in adolescents and young adults with sickle cell disease

  2017cites this paper
• Genetic Modifiers of White Blood Cell Count, Albuminuria and Glomerular Filtration Rate in Children with Sickle Cell Anemia

  2016cites this paper
• ENHANCE—(Electronic Hydroxyurea Adherence): A Protocol to Increase Hydroxyurea Adherence in Patients with Sickle Cell Disease

  2016cites this paper
• Rationale and design of mDOT-HuA study: a randomized trial to assess the effect of mobile-directly observed therapy on adherence to hydroxyurea in adults with sickle cell anemia in Tanzania

  2016cites this paper
• Minireview: Prognostic factors and the response to hydroxurea treatment in sickle cell disease

  2016cites this paper
• Emerging point-of-care technologies for sickle cell disease screening and monitoring

  2016cites this paper
• Clinical Course of Two Children with Unstable Hemoglobins: The Effect of Hydroxyurea Therapy

  2016cites this paper
• Development of a pharmacokinetic-guided dose individualization strategy for hydroxyurea treatment in children with sickle cell anaemia.

  2016cites this paper
• Hydroxyurea for reducing blood transfusion in non-transfusion dependent beta thalassaemias.

  2016cites this paper
• The Effect of Hydroxyurea Therapy in Bahraini Sickle Cell Disease Patients

  2016cites this paper
• Genetic Factors Modifying Sickle Cell Disease Severity

  2016cites this paper
• Adherence to Hydroxyurea Therapy in Patients with Sickle Cell Disease at King Khalid University Hospital in Riyadh

  2016cites this paper
• Systematic and Meta-Analytic Review: Medication Adherence Among Pediatric Patients With Sickle Cell Disease.

  2016influential citation
• The role of BCL11A and HMIP-2 polymorphisms on endogenous and hydroxyurea induced levels of fetal hemoglobin in sickle cell anemia patients from southern Brazil.

  2016cites this paper
• Neutrophils, platelets, and inflammatory pathways at the nexus of sickle cell disease pathophysiology.

  2016cites this paper
• SICKLE CELL DISEASE: CHALLENGES AND PROGRESS Neutrophils, platelets, and in fl ammatory pathways at the nexus of sickle cell disease pathophysiology

  2016cites this paper
• Inactivation of HDAC1 or HDAC2 induces gamma globin expression without altering cell cycle or proliferation

  2015cites this paper
• Severity of Brazilian sickle cell disease patients: severity scores and feasibility of the Bayesian network model use.

  2015cites this paper
• Pharmacotherapy of Sickle Cell Disease in Children.

  2015cites this paper
• Gum Arabic as fetal hemoglobin inducing agent in sickle cell anemia; in vivo study

  2015cites this paper
• HydroxyureaTherapy in Patients with Sickle Cell Disease

  2015cites this paper
• Sickle cell in sickle cell disease in Latin America and the United States

  2015cites this paper
• Low and fixed dose of hydroxyurea is effective and safe in patients with HbSβ+ thalassemia with IVS1‐5(G→C) mutation

  2015influential citation
• UMA ABORDAGEM SOBRE O USO DA HIDROXIUREIA E DO TRANSPLANTE DE CÉLULAS-TRONCO HEMATOPOÉTICAS NO TRATAMENTO DA ANEMIA FALCIFORME

  2014cites this paper
• A pilot study of electronic directly observed therapy to improve hydroxyurea adherence in pediatric patients with sickle‐cell disease

  2014influential citation
• The effect of hydroxyurea on compound heterozygotes for sickle cell‐hemoglobin D‐Punjab—A single centre experience in eastern India

  2014cites this paper
• Hydroxyurea in Sickle Cell Disease: Drug Review

  2014cites this paper
• Medication Adherence Among Pediatric Patients With Sickle Cell Disease: A Systematic Review abstract

  2014cites this paper
• Medication Adherence Among Pediatric Patients With Sickle Cell Disease: A Systematic Review

  2014cites this paper
• Systematic Review Medication Adherence Among Pediatric Patients With Sickle Cell Disease: A

  2014cites this paper
• Whole Exome Sequencing Identifies Novel Genes for Fetal Hemoglobin Response to Hydroxyurea in Children with Sickle Cell Anemia

  2014cites this paper
• Quantification of HBG mRNA in primary erythroid cultures: prediction of the response to hydroxyurea in sickle cell and beta‐thalassemia

  2014cites this paper
• treatment in sickle cell anemia Epigenetic and molecular profiles of erythroid cells after hydroxyurea

  2014cites this paper
• ß -Globin Gene Cluster Haplotypes and Clinical Severity in Sickle Cell Anemia Patients in Southern Brazil

  2014cites this paper
• Sickle cell disease.

  2014cites this paper
• Adherence to Hydroxyurea Therapy in Patients with Sickle Cell Disease at King Khalid University Hospital in Riyadh

  2014cites this paper
• Is Sickle Cell Trait as Benign as it is Usually Assumed

  2014cites this paper
• Intérêt du gemtuzumab ozogamicin dans les leucémies aiguës myéloïdes

  2014cites this paper
• Candidate Sequence Variants and Fetal Hemoglobin in Children with Sickle Cell Disease Treated with Hydroxyurea

  2013influential citation
• Optimizing Hydroxyurea use in children with sickle cell disease: low dose regimen is effective

  2013cites this paper
• Clinical and hematological effects of hydroxyurea therapy in sickle cell patients: a single-center experience in Brazil

  2013cites this paper
• Efficacy of fixed low dose hydroxyurea in Indian children with sickle cell anemia: A single centre experience

  2013cites this paper
• Sickle cell anemia: time for personalized prescription of hydroxyurea? Focus on "Organic anion transporting polypeptide 1B transporters modulate hydroxyurea pharmacokinetics".

  2013cites this paper
• Emerging Science of Hydroxyurea Therapy for Pediatric Sickle Cell Disease

  2013influential citation
• Genetic and biochemical markers of hydroxyurea therapeutic response in sickle cell anemia

  2013cites this paper
• In vitro modeling of the microvascular occlusion and thrombosis that occur in hematologic diseases using microfluidic technology.

  2012cites this paper
• Hydroxyurea for the treatment of sickle cell disease: Efficacy, barriers, toxicity, and management in children

  2012influential citation
• What Happened to Anti-CD33 Therapy for Acute Myeloid Leukemia?

  2012cites this paper
• Low Dose Hydroxyurea is Effective in Reducing the Incidence of Painful Crisis and Frequency of Blood Transfusion in Sickle Cell Anemia Patients from Eastern India

  2012cites this paper
• How I treat …

  2012cites this paper
• Low Fixed-Dose Hydroxyurea in Severely Affected Indian Children with Sickle Cell Disease

  2012cites this paper
• Hydroxycarbamide alters erythroid gene expression in children with sickle cell anaemia

  2012cites this paper
• Hydroxyurea in the treatment of children and adolescents with sickle cell anemia

  2012cites this paper
• The proinflammatory cytokine GM-CSF downregulates fetal hemoglobin expression by attenuating the cAMP-dependent pathway in sickle cell disease.

  2011cites this paper
• 1 Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics of Hydroxyurea Treatment for Children with Sickle Cell Anemia

  2011cites this paper
• Sickle cell disease.

  2011cites this paper
• Fetal Hemoglobin Levels in African American and Hispanic Children With Sickle Cell Disease at Baseline and in Response to Hydroxyurea

  2011influential citation
• Genetic modifiers of HbF and response to hydroxyurea in sickle cell disease

  2011cites this paper
• Epigenetic and molecular profiles of erythroid cells after hydroxyurea treatment in sickle cell anemia.

  2011cites this paper